Login to Your Account



Genentech Stretches Nutropin Markets With New Approvals

By Aaron Lorenzo


Friday, July 8, 2005
Genentech Inc. got the green light to expand its growth hormone market, as the FDA approved Nutropin (somatropin [rDNA origin] for injection) and Nutropin AQ (somatropin [rDNA origin] injection) for the long-term treatment of idiopathic short stature (ISS). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription